top of page


DeuterOncology’s lead product DO-2 is an improved MET kinase inhibitor, which is being developed as a potential ‘best in class’ targeted therapy for lung cancer.

The metabolically labile hydrogen has been replaced with a stronger bond strength deuterium atom that significantly reduces the importance of this metabolic liability.  In addition, the formation of an active metabolite has been shown, that maintains activity on the MET kinase as well as binding to an alternative kinase that is a constituent of the ras pathway. This new target kinase has been reported to play a role in the ras signaling pathway involved in resistance to MET inhibitors and represents a promising new target for overcoming or delaying the emergence of resistance.

DeuterOncology has initiated the Phase 1 clinical study in Q4 2022 to validate DO-2 as a ‘Best in Class’ MET kinase inhibitor as well as to identify a recommended phase 2 dose. The clinical study (EudraCT 2022-001681-35) is now open for recruitment of biomarker selected patients at two trial sites in Belgium (Prof Jean-Pascal Machiels ( and Dr Rachel Galot (, Cliniques universitaires Saint-Luc, UCLouvain Brussels and Prof Hans Prenen (, UZA Antwerp) and one site in the Netherlands (Dr Debbie Robbrecht ( ), Erasmus MC Rotterdam).

For more information click here  

bottom of page